Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D03FVR
|
|||
| Former ID |
DIB012008
|
|||
| Drug Name |
GSK-1827771
|
|||
| Synonyms |
IL-1 antagonist (antibody, rheumatoid arthritis), GSK
Click to Show/Hide
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Rheumatoid arthritis [ICD-11: FA20] | Phase 1 | [1] | |
| Company |
GlaxoSmithKline plc
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Interleukin 1 receptor type 2 (IL1R2) | Target Info | . | [2] |
| KEGG Pathway | MAPK signaling pathway | |||
| Cytokine-cytokine receptor interaction | ||||
| Hematopoietic cell lineage | ||||
| Amoebiasis | ||||
| HTLV-I infection | ||||
| Transcriptional misregulation in cancer | ||||
| NetPath Pathway | IL1 Signaling Pathway | |||
| TNFalpha Signaling Pathway | ||||
| Pathway Interaction Database | IL1-mediated signaling events | |||
| Reactome | Interleukin-1 signaling | |||
| WikiPathways | MAPK Signaling Pathway | |||
| Interleukin-1 signaling | ||||
| Apoptosis Modulation and Signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT00539760) A Phase I Rheumatoid Arthritis Study in Healthy Volunteers. U.S. National Institutes of Health. | |||
| REF 2 | WO patent application no. 2013,0077,63, Modulators of the nlrp3 inflammasome il-1ss pathway for the prevention and treatment of acne. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.